Literature DB >> 459949

Endotoxic glycolipid as a potent depressor of the hepatic drug-metabolizing enzyme systems in mice.

K Egawa, N Kasai.   

Abstract

Inhibitory effects of the endotoxic glycolipid from Salmonella minnesota R595 on hepatic drug-metabolizing enzyme activities in mice were investigated, and the depressor activity of the glycolipid in the enzyme systems was confirmed. Among degradation products of lipopolysaccharides tested, lipid A preparations derived from the mild acetic acid hydrolysates of lipopolysaccharides were the most active, but the lipid A fractions prepared from the hydrolysates with 1 N-HCl were almost inactive. A degraded polysaccharide fraction from E. coli lipopolysaccharide was inactive. The activities of the glycolipid and the lipid A preparation were markedly reduced by treatment with alkaline-hydroxylamine, mild alkali or hydrazine. The data showed that the lipid A moiety of the glycolipid may be responsible for the inhibitory activity on the hepatic drug-metabolizing enzyme systems.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 459949     DOI: 10.1111/j.1348-0421.1979.tb00444.x

Source DB:  PubMed          Journal:  Microbiol Immunol        ISSN: 0385-5600            Impact factor:   1.955


  3 in total

1.  Low endotoxic activities of synthetic Salmonella-type lipid A with an additional acyloxyacyl group on the 2-amino group of beta (1-6) glucosamine disaccharide 1,4'-bisphosphate.

Authors:  S Kotani; H Takada; I Takahashi; M Tsujimoto; T Ogawa; T Ikeda; K Harada; H Okamura; T Tamura; S Tanaka
Journal:  Infect Immun       Date:  1986-06       Impact factor: 3.441

2.  Synthetic Salmonella-type lipid A antigen with high serological specificity.

Authors:  N Kasai; S Arata; J Mashimo; K Okuda; Y Aihara; S Kotani; H Takada; T Shiba; S Kusumoto; M Imoto
Journal:  Infect Immun       Date:  1986-01       Impact factor: 3.441

3.  Immunobiological activities of synthetic lipid A analogs and related compounds as compared with those of bacterial lipopolysaccharide, re-glycolipid, lipid A, and muramyl dipeptide.

Authors:  S Kotani; H Takada; M Tsujimoto; T Ogawa; Y Mori; M Sakuta; A Kawasaki; M Inage; S Kusumoto; T Shiba; N Kasai
Journal:  Infect Immun       Date:  1983-08       Impact factor: 3.441

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.